Spero Therapeutics, Inc. (SPRO) Net margin 2016–2025
Spero Therapeutics, Inc. (SPRO) net profit margin by fiscal year — reported net income divided by reported revenue.
68.1%FY2025 · since FY2016: -7609.3% → 68.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 68.1% | +18549.5 pp |
| FY2024 | -18481.4% | -20925.8 pp |
| FY2023 | 2444.4% | +4298.7 pp |
| FY2022 | -1854.4% | +1070.7 pp |
| FY2021 | -2925.1% | +27423.8 pp |
| FY2020 | -30348.8% | -29064.6 pp |
| FY2019 | -1284.3% | -232.8 pp |
| FY2018 | -1051.4% | +906.3 pp |
| FY2017 | -1957.7% | +5651.5 pp |
| FY2016 | -7609.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRO financial trends
SPRO RevenueSPRO Net incomeSPRO Gross profitSPRO Gross marginSPRO Operating incomeSPRO Operating marginSPRO Operating cash flowSPRO Free cash flowSPRO Capital expendituresSPRO Return on equitySPRO Stock buybacksSPRO Dividends paidSPRO Total assetsSPRO Total liabilitiesSPRO Shareholders’ equitySPRO overview →